Stratification of Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies-Reference-Cited by-同舟云学术

Stratification of Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies

Published:2021-05 Issue:3 Volume:7 Page:566-573
ISSN:2405-4569
Container-title:European Urology Focus
language:en
Short-container-title:European Urology Focus

Author:

Soria Francesco,D’Andrea David,Abufaraj Mohammad,Moschini Marco,Giordano Andrea,Gust Kilian M.,Karakiewicz Pierre I.,Babjuk Marek,Gontero Paolo,Shariat Shahrokh F.

Publisher

Elsevier BV

Subject

Urology

Reference16 articles.

1. Epidemiology and risk factors of urothelial bladder cancer;Burger;Eur Urol,2013

2. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients;Gontero;Eur Urol,2015

3. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin;Cambier;Eur Urol,2016

4. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update;Babjuk;Eur Urol,2019

5. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance;Oddens;Eur Urol,2013

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non–muscle-invasive Bladder Cancer;European Urology Oncology;2024-06

2. Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration;European Urology Oncology;2024-06

3. Adjuvant intravesical therapy in intermediate‐risk non‐muscle‐invasive bladder cancer;BJU International;2024-04-16

4. Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer;Bioactive Materials;2024-01

5. Reply to Letter to Editor: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer;Annals of Surgical Oncology;2023-09-27